Login to Your Account



ExonHit Partners With IDEC To Develop Antibody Therapeutics

By James Etheridge


Wednesday, January 9, 2002
PARIS - ExonHit Therapeutics SA and IDEC Pharmaceuticals Corp. signed a collaboration and research agreement aimed at discovering new antigen targets for antibody therapy, with a particular focus on prostate carcinoma.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription